Summit Therapeutics (SMMT) Cash & Current Investments (2017 - 2026)

Summit Therapeutics (SMMT) has reported Cash & Current Investments for 10 consecutive years, with $690.7 million the latest figure, recorded in Q2 2026.

• Quarterly Cash & Current Investments rose 131.62% year-over-year to $690.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $690.7 million (up 131.62% YoY) and the FY2025 annual result came in at $713.4 million, up 73.02% from the prior year.
• Cash & Current Investments rose to $690.7 million in Q2 2026 per SMMT's latest filing, from $598.7 million in the prior quarter.
• Over the last five years, Cash & Current Investments for SMMT reached as high as $713.4 million in Q4 2025 and fell as low as $28.8 million in Q2 2024.
• A 5-year average of $302.9 million and a median of $226.9 million in 2023 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2023 — Cash & Current Investments plunged 88.99% — and 2025, when it surged 937.04%.
• Year by year, Cash & Current Investments stood at $648.6 million in 2022, then tumbled by 88.99% to $71.4 million in 2023, then jumped by 477.32% to $412.3 million in 2024, then jumped by 73.02% to $713.4 million in 2025, then decreased by 3.19% to $690.7 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $690.7 million, $598.7 million, and $713.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.